drugset / Trial / NCT05345327
SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes
Phase 3
Recruiting
994 enrolled
The George Institute
Monash University · collabThe University of New South Wales · collabUniversity of Sydney · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The aim of the trial is to evaluate the effects of the SGLT2 inhibitor, dapagliflozin, compared to metformin on annual decline in eGFR when used as first line therapy in people with Type 2 Diabetes.
Timeline
- Start
- 2023-01-01
- Primary completion
- 2026-06-30
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dapagliflozin | Small molecule | 10 mg | Oral |
| Comparator | Metformin | Small molecule | 2000 mg | Oral |